GlassScriptPhysician profile
Daniel Lyman Miller
NPI 1508032525
$4,221.92
in general payments reported to CMS, 2019-2025
40 companies · $775 in 2025
The $775 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,139 · 2020: $328 · 2021: $64.30 · 2022: $294 · 2023: $435 · 2024: $188 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381 · Gift: $16.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.53 |
| Gift | $16.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,396.11 | 2019-2020 | |
| Astellas Pharma US INC | $548.33 | 2019-2023 | Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $192.85 | 2019-2025 | |
| Pfizer INC. | $147.34 | 2019-2025 | |
| Ambu INC. | $143.77 | 2025 | |
| Procept Biorobotics Corporation | $140.33 | 2025 | |
| Ferring Pharmaceuticals INC. | $118.88 | 2019-2025 | Adstiladrin |
| Abbvie INC. | $117.59 | 2019-2023 | |
| Rochester Medical Corporation | $109.76 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $109.31 | 2022-2025 | Prolaris, Myrisk |
| Angiodynamics, INC. | $85.32 | 2022 | |
| Progenics Pharmaceuticals, INC. | $83.36 | 2023-2025 | Pylarify |
| Accord Healthcare, INC. | $80.46 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $78.89 | 2019-2023 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $74.89 | 2023 | Gemtesa |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $67.30 | 2023-2024 | |
| Urogen Pharma, INC. | $67.24 | 2022-2025 | |
| Allergan, INC. | $53.83 | 2019 | |
| Boston Scientific Corporation | $51.30 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $48.14 | 2023 | Oxlumo |
| Coloplast Corp | $46.63 | 2021-2025 | |
| Olympus America INC. | $43.48 | 2025 | Itind System |
| Janssen Biotech, INC. | $41.66 | 2019 | |
| Travere Therapeutics, INC. | $36.30 | 2019-2022 | |
| 180 Medical, INC. | $29.05 | 2025 | Cure Catheter |
| Dendreon Pharmaceuticals LLC | $28.44 | 2019 | |
| Axonics, INC. | $25.21 | 2024 | Axonics |
| Amgen INC. | $25.17 | 2019 | |
| Teleflex LLC | $24.40 | 2025 | Barrigel |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Agiliti Surgical, INC. | $23.77 | 2019 | |
| Valencia Technologies Corporation | $21.64 | 2025 | Ecoin Device Kit |
| Convatec INC. | $20.00 | 2019 | |
| Endo USA, INC. | $19.03 | 2025 | Xiaflex |
| Antares Pharma, INC. | $18.75 | 2020 | |
| Ethicon US, LLC | $18.21 | 2024 | Echelon; Endopath |
| Baxter Healthcare | $16.94 | 2024 | Perclot |
| Merck Sharp & Dohme LLC | $14.89 | 2025 | Bridion |
| Therapeuticsmd, INC. | $14.82 | 2019 | |
| Becton, Dickinson and Company | $14.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.